Bio-Techne: Geist disposes of 22,545 stock options

The reported activity spans performance options, performance and standard RSUs, and common shares, with RSU vesting dates running through August 15, 2028.

Available on EDGAR 11/02/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:36 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

BIO-TECHNE Corp (TECH) President, Protein Sciences William Geist reported direct transactions dated August 15, 2026. The transaction table lists disposition to the issuer of 22,545 performance stock options, with 1,879 options following the transaction; a note says the board authorized discretionary vesting for 1,879 options and the remainder were forfeited. The table also lists disposition of 698 performance RSUs and exercise/conversion entries for 8,376 performance RSUs, 2,623 RSUs and 3,226 RSUs. Notes state discretionary vesting was authorized for 698 performance RSUs, 2,623 RSUs vest on August 15, 2027, and 3,226 RSUs vest on each of August 15, 2027 and August 15, 2028. Other entries show acquisition of 6,547 common shares and 2,019 shares delivered or withheld for payment of exercise price or tax liability; the listed option exercise price is $84.61 and the 2,019-share transaction price is $72.40 per share.

Insider Trade Summary

14,225 shares exercised/converted

Exercise 7 txns

Insider Geist William

Role PRESIDENT, PROTEIN SCIENCES

Type	Security	Shares	Price	Value
Disposition	Performance Stock Options (Right to Buy) ^F1	22,545	$0.00	$0.00
Disposition	Performance Restricted Stock Units ^{F2, F3}	698	$0.00	$0.00
Exercise	Performance Restricted Stock Units ^{F2, F3}	8,376	$0.00	$0.00
Exercise	Restricted Stock Units ^{F2, F4}	2,623	$0.00	$0.00
Exercise	Restricted Stock Units ^{F2, F5}	3,226	$0.00	$0.00
Exercise	Common Stock	6,547	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,019	$72.40	$146K

Holdings After Transaction: Performance Stock Options (Right to Buy) — 1,879 contracts (Direct); Performance Restricted Stock Units — 0 contracts (Direct); Restricted Stock Units — 9,075 contracts (Direct); Common Stock — 25,031 shares (Direct)

Footnotes (5)

F1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,879 performance options. The remainder of the performance options were forfeited.
F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 698 performance RSUs. The remainder of the performance RSUs were forfeited.
F4. 2,623 restricted stock units vest on 8/15/2027.
F5. 3,226 restricted stock units vest on each of 8/15/2027 and 8/15/2028.

Key Figures

Performance stock options disposed to issuer: 22,545 options Performance options following transaction: 1,879 options Option exercise price: $84.61 per option +5 more

8 metrics

Performance stock options disposed to issuer 22,545 options Transaction dated August 15, 2026

Performance options following transaction 1,879 options After the transaction dated August 15, 2026

Option exercise price $84.61 per option Performance stock options

Performance RSUs with discretionary vesting authorized 698 RSUs Board authorization dated August 15, 2026

Performance RSUs in exercise/conversion entry 8,376 RSUs Transaction dated August 15, 2026

Scheduled RSU vesting 2,623 RSUs on August 15, 2027; 3,226 RSUs on each of August 15, 2027 and August 15, 2028 Vesting dates stated in the notes

Common shares acquired 6,547 shares Transaction dated August 15, 2026

Shares delivered or withheld for payment 2,019 shares at $72.40 per share Transaction dated August 15, 2026

Key Terms

Performance Stock Options (Right to Buy), Performance Restricted Stock Units, discretionary vesting, contingent right

4 terms

Performance Stock Options (Right to Buy) technical

"Performance Stock Options (Right to Buy)"

Performance Restricted Stock Units technical

"Performance Restricted Stock Units"

Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.

discretionary vesting technical

"authorized discretionary vesting for 1,879 performance options"

contingent right technical

"contingent right to receive one share of Bio-Techne common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did William Geist report for TECH?

William Geist, Bio-Techne's President, Protein Sciences, reported disposition to the issuer of 22,545 performance stock options, acquisition of 6,547 common shares, and 2,019 shares delivered or withheld for payment of exercise price or tax liability. The report also lists RSU transactions, including units scheduled to vest in 2027 and 2028. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geist William

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT, PROTEIN SCIENCES

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/18/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2026		M		6,547	A	$0	27,050	D
Common Stock	08/15/2026		F		2,019	D	$72.4	25,031	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Options (Right to Buy)	$84.61	08/15/2026		D			22,545	⁽¹⁾	⁽¹⁾	Common Stock	22,545	$0	1,879	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		D			698	⁽³⁾	⁽³⁾	Common Stock	698	$0	8,376	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		M			8,376	⁽³⁾	⁽³⁾	Common Stock	8,376	$0	0	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			2,623	⁽⁴⁾	⁽⁴⁾	Common Stock	2,623	$0	2,623	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			3,226	⁽⁵⁾	⁽⁵⁾	Common Stock	3,226	$0	6,452	D

Explanation of Responses:

1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,879 performance options. The remainder of the performance options were forfeited.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 698 performance RSUs. The remainder of the performance RSUs were forfeited.

4. 2,623 restricted stock units vest on 8/15/2027.

5. 3,226 restricted stock units vest on each of 8/15/2027 and 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR